Bryan Mobley July 14, 2019

Asia-Pacific Cancer Biomarkers

Asia-Pacific Cancer Biomarkers Market offer significant and proficient insights into the current market scenario and the emerging growth dynamics. The report on Asia-Pacific Cancer Biomarkers Market provides the market players as well as the new visitors to show complete view of the market landscape. The comprehensive research will enable the well-established as well as the emerging players to establish their business strategies and achieve their short-term and long-term goals. The report also presents a significant evaluation of the scope of the regions and where the key participants might find potential growth opportunities in future.

Request a sample copy of the report – https://www.marketreportsworld.com/enquiry/request-sample/12346242

The Asia-Pacific Cancer Biomarkers Market players influencing the market are profiled in the study along with their SWOT analysis and market strategies. The report also focuses on leading industry players with information such as company profiles, products and services offered financial information of last 3 years, key development in past five years.

The Asia-Pacific cancer biomarkers market is expected to register a good CAGR during the forecast period of 2018–2023. Biomarkers are chemical, physical or biological parameters, which can be used to indicate disease states. Oncology biomarkers offer high speed, non-invasive cancer diagnosis and are believed to enhance cancer detection and screening. Major driving factors for the market are streamlined drug delivery process, noninvasive technology, and increased rates of survival.

Paradigm Shift in Healthcare from Disease Diagnosis to Risk Assessment or Early Diagnosis

There has been a paradigm shift in healthcare, from diagnosis after the symptom has appeared to early diagnosis or risk assessment, especially in developed countries, such as the china, India, Japan, and others. Cancer biomarkers play a pivotal role in risk assessment and early diagnosis. Biomarkers, particularly those associated with genetic factors, offer a quantitative way to determine when individuals are predisposed to some form of cancer. These biomarkers have been developed for almost all cancers with high prevalence rate. Some of the examples of such biomarkers are the mutation on KRAS, p53, EGFR, erbB2 for colorectal, esophageal, liver and pancreatic cancer, and BRCA1 and BRCA2 for breast and ovarian cancer. The biomarker’s potential to assess the risk precisely has helped in improving the adoption of the technology, which has led to market expansion.
In cancer, it is widely accepted that the success of the treatment depends on the phase that it is being diagnosed in. Some even suggest the 80-20 formula, which indicates that if cancer has been diagnosed in stage one, the success rate of treatment could be as high as 80%. This underlines the importance of early diagnosis. Biomarkers have the potential to improve the early diagnosis process significantly in terms of accuracy and efficiency. This capability of precise early diagnosis is one of the most important reasons for the adoption of the technology, which is going to drive the market. The other factor, such as an increasing usage of biomarkers in drug development is driving the cancer biomarker market.

Need for Immediate Processing

It is proposed that both tissue and blood should be profiled in parallel within the single cancer-specific platform. Blood is very useful as a starting point due to its ease of acquisition, the diversity of analytes it contains, and its practicality. Moreover, most disease-relevant biomarkers are expected to be at their highest concentration at relevant organs or tissues. The need for immediate processing, storage, and thawing of these specimens is another restraining factor for the cancer biomarker tests, because the viability of the cells is very important while performing different biomarker tests. The other factors, such as the high cost of diagnosis and reimbursement issues are also hindering the growth of the Asia-Pacific cancer biomarker market.

China Leads the Market

The China cancer biomarker market held the largest market share in 2017 in the Asia-Pacific region due to the presence of better quality healthcare systems and the high rate of prevalence of cancer in this region, which is expected to increase in the coming years.

Key Developments in the Market

• January 2018: Roche and GE have entered into a partnership to develop the integrated digital diagnostics platform to improve oncology and critical care treatment. This partnership will apply advanced analytics to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from Roche’s biomarker, tissue pathology, genomics, and sequencing portfolio.
• January 2018: New biomarkers found for colorectal cancer (MYO5B).
• November 2017: Researchers find a new biomarker for breast cancer (GIRK1).
• October 2017: ABBOTT acquired ALERE.

Major players: ABBOTT LABORATORIES, AFFYMETRIX INC., (THERMO FISHER SCIENTIFIC), AGILENT TECHNOLOGIES, HOLOGIC INC., ROCHE HOLDING AG, BIOMERIEUX, CELERA CORPORATION (QUEST DIAGNOSTICS), and ILLUMINA INC., among others.

Reasons to Purchase the Report

• Follow the current and future Asia-Pacific cancer biomarker market in the developed and emerging markets.
• Examining the various perspectives of the market with the help of Porter’s Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support along with the Market Estimate sheet (in Excel).

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Enquire before purchasing this report –https://www.marketreportsworld.com/enquiry/pre-order-enquiry/12346242   

Asia-Pacific Cancer Biomarkers Market Analyse according to leading players, Competitive landscape, geographical regions, top manufacturers, types, and applications forecast over a period of 2019 to 2024. Geographically, this report is divided into many key Regions, with production, consumption, revenue (million USD), market share and rate of Asia-Pacific Cancer Biomarkers Market 2019 in these regions, from 2018 to 2024 (forecast), covering: North America, China, Europe, Japan, Southeast Asia, India.

The Objectives of this report are:

  • To define, describe, and analyze the Asia-Pacific Cancer Biomarkers market on the basis of product type, application, and region
  • To forecast and analyze the size of the Asia-Pacific Cancer Biomarkers market (in terms of value) in six key regions, namely, Asia Pacific, Western Europe, Central & Eastern Europe, North America, the Middle East & Africa, and South America
  • To forecast and analyze the Asia-Pacific Cancer Biomarkers market at country-level in each region
  • To strategically analyze each submarket with respect to individual growth trends and its contribution to the Asia-Pacific Cancer Biomarkers market
  • To analyze opportunities in the Asia-Pacific Cancer Biomarkers market for stakeholders by identifying high-growth segments of the market

Key Questions Answered in Asia-Pacific Cancer Biomarkers market report:

  • What will the market size be in 2024 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Purchase this report (Price 3850 USD for a single-user license) – https://www.marketreportsworld.com/purchase/12346242

Asia-Pacific Cancer Biomarkers Market Report Provides Comprehensive Analysis as Following:

Market segments and sub-segments

Market size & shares

Market trends and dynamics

Market Drivers and Opportunities

Market Analysis and Segmentation

Competitive landscape

Supply and demand

Technological inventions in Asia-Pacific Cancer Biomarkers trade

Marketing Channel Development Trend

Asia-Pacific Cancer Biomarkers Market Positioning

Pricing Strategy

Brand Strategy

Target consumer

Distributors/Traders List enclosed in Positioning Asia-Pacific Cancer Biomarkers Market

Asia-Pacific Cancer Biomarkers Market report provides you a visible, one-stop breakdown of the leading product, submarkets and market leaders revenue forecasts till 2024. In conclusion, Asia-Pacific Cancer Biomarkers Market 2019 report presents the descriptive analysis of the Asia-Pacific Cancer Biomarkers Market Major Key-players, Types, Application and Forecast Period knowledge which is able to function a profitable guide for all the Asia-Pacific Cancer Biomarkers Market competitors.

About Us: –

Market Reports World is the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today’s businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email: [email protected]

Phone: US +1 424 253 0807 /UK +44 203 239 8187

For Our Other Report:-

Global Safety Relay Market 2019-2023 Research Analysis by CAGR, Production, Growth & Opportunities|MarketReportsworld.com